Celcuity Inc. 8-K — AI Bull & Bear Analysis

The filing marks a critical transition for Celcuity as it trades immediate debt pressure for long-term equity risk. While the successful closing of the offering and the full exercise of the underwriters' over-allotment option suggest strong market appetite, the company remains a high-risk biotech play. Investors must now weigh the benefit of a cleaner immediate balance sheet against the long-term threat of a $575 million liability that could either convert into a flood of new shares or require a massive cash repayment in 2032.